Osteoclast activity and subtypes as a function of physiology and pathology - Implications for future treatments of osteoporosis

Endocrine Reviews

Volumn 32, Issue 1, 2011, Pages 31-63

  Henriksen, K ^a   Bollerslev, J ^b   Everts, V ^c   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBONATE DEHYDRATASE II; CATHEPSIN K; CATHEPSIN K INHIBITOR; COLLAGEN TYPE 1; DENOSUMAB; EPHRIN B2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE B; GLUCAGON LIKE PEPTIDE 2; PARATHYROID HORMONE; SOMATOMEDIN C; STRONTIUM RANELATE; TRANSFORMING GROWTH FACTOR BETA;

ALBERS SCHOENBERG DISEASE; ANION EXCHANGE; ARTHRITIS; BONE REMODELING; CELL TYPE; ENCHONDRAL OSSIFICATION; HORMONE SUBSTITUTION; HUMAN; JAW OSTEONECROSIS; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TRABECULAR BONE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE RESORPTION; HUMANS; MICE; OSTEITIS DEFORMANS; OSTEOCLASTS; OSTEOPOROSIS; RANK LIGAND; RATS;

EID: 79951655957     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2010-0006     Document Type: Review

References (380)

1. Segovia-Silvestre T, Neutzsky-Wulff AV, Sorensen MG, Christiansen C, Bollerslev J, Karsdal MA, Henriksen K 2009 Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet 124:561-577
2. Everts V, de Vries TJ, Helfrich MH 2009 Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions. Biochim Biophys Acta 1792:757-765
3. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K 2007 Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487-494
4. Everts V, Korper W, Jansen DC, Steinfort J, Lammerse I, Heera S, Docherty AJ, Beertsen W 1999 Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 13:1219-1230 (Pubitemid 29300367)
5. Marks Jr SC 1983 The origin of osteoclasts: evidence, clinical implications and investigative challenges of an extraskeletal source. J Oral Pathol 12:226-256
6. Leeming DJ, Henriksen K, Byrjalsen I, Qvist P, Madsen SH, Garnero P, Karsdal MA 2009 Is bone quality associated with collagen age? Osteoporos Int 20:1461-1470
7. Henriksen K, Leeming DJ, Byrjalsen I, Nielsen RH, Sorensen MG, Dziegiel MH, Martin TJ, Christiansen C, Qvist P, Karsdal MA 2007 Osteoclasts prefer aged bone. Osteoporos Int 18:751-759 (Pubitemid 46684778)
8. Karsdal MA, Henriksen K, Sørensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J 2005 Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467-476 (Pubitemid 40189043)
9. Martin TJ, Sims NA 2005 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81 (Pubitemid 40193486)
10. Martin TJ, Quinn JM, Gillespie MT, Ng KW, Karsdal MA, Sims NA 2006 Mechanisms involved in skeletal anabolic therapies. Ann NY Acad Sci 1068:458-470 (Pubitemid 43824174)
11. Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K 2008 Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 366:483-488 (Pubitemid 50010416)
12. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K 2006 Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111-121 (Pubitemid 44138718)
13. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ 2008 Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA 105:20764-20769
14. Seeman E, Delmas PD 2006 Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
15. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA 2009 Local communication on and within bone controls bone remodeling. Bone 44:1026-1033
16. Chavassieux P, Seeman E, Delmas PD 2007 Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev 28:151-164 (Pubitemid 46984832)
17. Takahashi H, Epker B, Frost HM 1964 Resorption precedes formative activity. Surg Forum 15:437-438
18. Hattner R, Epker BN, Frost HM 1965 Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206:489-490
19. Parfitt AM 1982 The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 4:1-6
20. Martin TJ 1993 Hormones in the coupling of bone resorption and formation. Osteoporos Int 3(Suppl 1):121-125 (Pubitemid 23099909)
21. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N 2003 Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441-5449 (Pubitemid 37476073)
22. Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649 (Pubitemid 36917505)
23. Goltzman D 2002 Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 1:784-796 (Pubitemid 37361562)
24. Martin TJ, Seeman E 2007 New mechanisms and targets in the treatment of bone fragility. Clin Sci (Lond) 112:77-91 (Pubitemid 46120088)
25. Harvey N, Earl S, Cooper C 2006 Epidemiology of osteoporotic fractures. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Chap 42. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 244-248
26. Albers-Schönberg HE 1904 Röntgenbilder einer seltenen Knockenerkrankung. 5th ed. Munch. Med. Wochenschr, Münich: Germany; 365-368
27. Tolar J, Teitelbaum SL, Orchard PJ 2004 Osteopetrosis. N Engl J Med 351:2839-2849
28. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH 2007 Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39:960-962 (Pubitemid 47185178)
29. Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, Vezzoni P, Villa A, Frattini A 2008 Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 83:64-76 (Pubitemid 351916706)
30. Henriksen K, Gram J, Høegh-Andersen P, Jemtland R, Ueland T, Dziegiel MH, Schaller S, Bollerslev J, Karsdal MA 2005 Osteoclasts from patients with autosomal dominant osteopetrosis type I (ADOI) caused by a T253I mutation in LRP5 are normal in vitro, but have decreased resorption capacity in vivo. Am J Pathol 167:1341-1348 (Pubitemid 41541420)
31. Glass 2nd DA, Karsenty G 2006 Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. Ann NY Acad Sci 1068:117-130 (Pubitemid 43824143)
32. Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA 2007 Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18:681-685 (Pubitemid 46525540)
33. Teitelbaum SL 2007 Osteoclasts: what do they do and how do they do it? Am J Pathol 170:427-435
34. Hayman AR, Jones SJ, Boyde A, Foster D, Colledge WH, Carlton MB, Evans MJ, Cox TM 1996 Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 122:3151-3162 (Pubitemid 26371980)
35. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE 1983 Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 80:2752-2756 (Pubitemid 13093387)
36. Gelb BD, Shi GP, Chapman HA, Desnick RJ 1996 Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238
37. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A 2000 Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25:343-346 (Pubitemid 30437326)
38. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z 1998 MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411-422 (Pubitemid 28232085)
39. Kornak U, Kasper D, Bösl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ 2001 Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205-215 (Pubitemid 32174837)
40. Chalhoub N, Benachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, Villa A, Vacher J 2003 Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 9:399-406 (Pubitemid 36460073)
41. Findlay DM, Martin TJ 1997 Receptors of calciotropic hormones. Horm Metab Res 29:128-134 (Pubitemid 27209916)
42. Del Fattore A, Cappariello A, Teti A 2008 Genetics, pathogenesis and complications of osteopetrosis. Bone 42:19-29 (Pubitemid 350297169)
43. Väänänen HK, Horton M 1995 The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 108:2729-2732
44. Roodman GD 1999 Cell biology of the osteoclast. Exp Hematol 27:1229-1241 (Pubitemid 29347472)
45. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342 (Pubitemid 40852708)
46. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL 2007 Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 176:877-888 (Pubitemid 46425547)
47. Meadows NA, Sharma SM, Faulkner GJ, Ostrowski MC, Hume DA, Cassady AI 2007 The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor. J Biol Chem 282:1891-1904 (Pubitemid 47076682)
48. Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ, Fisher DE 2001 Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci USA 98:5798-5803 (Pubitemid 32435722)
49. Luchin A, Purdom G, Murphy K, Clark MY, Angel N, Cassady AI, Hume DA, Ostrowski MC 2000 The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. J Bone Miner Res 15:451-460 (Pubitemid 30134089)
50. Zhao H, Laitala-Leinonen T, Parikka V, Väänänen HK 2001 Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J Biol Chem 276:39295-39302
51. Rodan GA, Martin TJ 2000 Therapeutic approaches to bone diseases. Science 289:1508-1514
52. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S 1989 Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855-857 (Pubitemid 19223662)
53. Blair HC, Teitelbaum SL, Tan HL, Koziol CM, Schlesinger PH 1991 Passive chloride permeability charge coupled to H(+)-ATPase of avian osteoclast ruffled membrane. Am J Physiol 260:C1315-C1324
54. Baron R, Neff L, Louvard D, Courtoy PJ 1985 Cell-mediated extracellular acidification and bone resorption: evidence for a lowpHin resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 101:2210-2222 (Pubitemid 16169951)
55. Scimeca JC, Franchi A, Trojani C, Parrinello H, Grosgeorge J, Robert C, Jaillon O, Poirier C, Gaudray P, Carle GF 2000 The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 26:207-213 (Pubitemid 30101642)
56. Li YP, Chen W, Liang Y, Li E, Stashenko P 1999 Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 23:447-451
57. Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, Hasan C, Bode U, Jentsch TJ, Kubisch C 2000 Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 9:2059-2063 (Pubitemid 30642671)
58. Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA 2004 Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537-1545 (Pubitemid 38529756)
59. Graves AR, Curran PK, Smith CL, Mindell JA 2008 The Cl(-)/H(+) antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453:788-792 (Pubitemid 351793780)
60. Weinert S, Jabs S, Supanchart C, Schweizer M, Gimber N, Richter M, Rademann J, Stauber T, Kornak U, Jentsch TJ 2010 Lysosomal pathology and osteopetrosis upon loss of H+-driven lysosomal Cl- accumulation. Science 328:1401-1403
61. Josephsen K, Praetorius J, Frische S, Gawenis LR, Kwon TH, Agre P, Nielsen S, Fejerskov O 2009 Targeted disruption of the Cl-/HCO3- exchanger Ae2 results in osteopetrosis in mice. Proc Natl Acad Sci USA 106:1638-1641
62. Jansen ID, Mardones P, Lecanda F, de Vries TJ, Recalde S, Hoeben KA, Schoenmaker T, Ravesloot JH, van Borren MM, van Eijden TM, Bronckers AL, Kellokumpu S, Medina JF, Everts V, Oude Elferink RP 2009 Ae2a,b-Deficient mice exhibit osteopetrosis of long bones but not of calvaria. FASEB J 23:3470-3481
63. Wu J, Glimcher LH, Aliprantis AO 2008 HCO3-/Cl- anion exchanger SLC4A2 is required for proper osteoclast differentiation and function. Proc Natl Acad Sci USA 105:16934-16939
64. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA 1996 Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 271:12517-12524 (Pubitemid 26160924)
65. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K 1998 Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453-13458 (Pubitemid 28522993)
66. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I 1999 Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654-1663 (Pubitemid 29455813)
67. Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, Desnick RJ, Gelb BD 1999 Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14:1902-1908
68. Everts V, Delaissé JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W 2002 The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17:77-90 (Pubitemid 33150999)
69. Henriksen K, Sørensen MG, Nielsen RH, Gram J, Schaller S, Dziegiel MH, Everts V, Bollerslev J, Karsdal MA 2006 Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J Bone Miner Res 21:58-66 (Pubitemid 43023227)
70. Everts V, Korper W, Hoeben KA, Jansen ID, Bromme D, Cleutjens KB, Heeneman S, Peters C, Reinheckel T, Saftig P, Beertsen W 2006 Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 21:1399-1408 (Pubitemid 44300046)
71. Shorey S, Heersche JN, Manolson MF 2004 The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula. Bone 35:909-917 (Pubitemid 39349222)
72. Salo J, Lehenkari P, Mulari M, Metsikkö K, Väänänen HK 1997 Removal of osteoclast bone resorption products by transcytosis. Science 276:270-273 (Pubitemid 27172688)
73. Nesbitt SA, Horton MA 1997 Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276:266-269 (Pubitemid 27172687)
74. Baron R 2005 General principles of bone biology. In: Rosen CJ, Compston JE, Lian JB, eds. Primer on the metabolic bone diseases and disorders of mineral metabolism. Chap 1. 5th ed. Hoboken, NJ: Wiley; 1-8
75. Bollerslev J 1989 Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr Rev 10:45-67 (Pubitemid 19156367)
76. Perez-Amodio S, Jansen DC, Schoenmaker T, Vogels IM, Reinheckel T, Hayman AR, Cox TM, Saftig P, Beertsen W, Everts V 2006 Calvarial osteoclasts express a higher level of tartrate-resistant acid phosphatase than long bone osteoclasts and activation does not depend on cathepsin K or L activity. Calcif Tissue Int 79:245-254
77. Hollberg K, Hultenby K, Hayman A, Cox T, Andersson G 2002 Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. Exp Cell Res 279:227-238 (Pubitemid 35217551)
78. Roberts HC, Knott L, Avery NC, Cox TM, Evans MJ, Hayman AR 2007 Altered collagen in tartrate-resistant acid phosphatase (TRAP)-deficient mice: a role for TRAP in bone collagen metabolism. Calcif Tissue Int 80:400-410 (Pubitemid 46956770)
79. van den Bos T, Speijer D, Bank RA, Brömme D, Everts V2008 Differences in matrix composition between calvaria and long bone in mice suggest differences in biomechanical properties and resorption: special emphasis on collagen. Bone 43:459-468
80. Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, Henriksen K, Lenhard T, Foged NT, Werb Z, Delaissé JM 2000 Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 151:879-889
81. Delaissé JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L 2003 Matrix metalloproteinases (MMP)and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 61:504-513 (Pubitemid 36890583)
82. Shibata S, Yamashita Y 2001 An ultrastructural study of osteoclasts and chondroclasts in poorly calcified mandible induced by high doses of strontium diet to fetal mice. Ann Anat 183:357-361 (Pubitemid 32685111)
83. Bromley M, Woolley DE 1984 Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 27:968-975 (Pubitemid 14004758)
84. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, Altman RD, Christiansen C 2008 Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 16:638-646
85. Mansell JP, Collins C, Bailey AJ 2007 Bone, not cartilage, should be the major focus in osteoarthritis. Nat Clin Pract Rheumatol 3:306-307 (Pubitemid 46864879)
86. Ortega N, Behonick DJ, Werb Z 2004 Matrix remodeling during endochondral ossification. Trends Cell Biol 14:86-93 (Pubitemid 38186642)
87. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 397:315-323
88. Wiktor-Jedrzejczak W, Bartocci A, Ferrante Jr AW, Ahmed-Ansari A, Sell KW, Pollard JW, Stanley ER 1990 Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 87:4828-4832
89. Wiktor-Jedrzejczak W, Urbanowska E, Aukerman SL, Pollard JW, Stanley ER, Ralph P, Ansari AA, Sell KW, Szperl M 1991 Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol 19:1049-1054
90. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571 (Pubitemid 30118482)
91. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N 1999 VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628 (Pubitemid 29289424)
92. Blavier L, Delaissé JM 1995 Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 108:3649-3659 (Pubitemid 26004028)
93. Dieudonné SC, Foo P, van Zoelen EJ, Burger EH 1991 Inhibiting and stimulating effects of TGF-β1 on osteoclastic bone resorption in fetal mouse bone organ cultures. J Bone Miner Res 6:479-487
94. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P 1993 Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 90:4485-4489 (Pubitemid 23148929)
95. Neutzsky-Wulff AV, Karsdal MA, Henriksen K 2008 Characterization of the bone phenotype in ClC-7-deficient mice. Calcif Tissue Int 83:425-437
96. Bollerslev J, Steiniche T, Melsen F, Mosekilde L 1989 Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone 10:19-24 (Pubitemid 19134740)
97. Bollerslev J, Marks Jr SC, Pockwinse S, Kassem M, Brixen K, Steiniche T, Mosekilde L 1993 Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14:865-869 (Pubitemid 24012696)
98. Nordahl J, Andersson G, Reinholt FP 1998 Chondroclasts and osteoclasts in bones of young rats: comparison of ultrastructural and functional features. Calcif Tissue Int 63:401-408 (Pubitemid 28476330)
99. Sawae Y, Sahara T, Sasaki T 2003 Osteoclast differentiation at growth plate cartilage-trabecular bone junction in newborn rat femur. J Electron Microsc (Tokyo) 52:493-502 (Pubitemid 38092537)
100. Pennypacker B, Shea M, Liu Q, Masarachia P, Saftig P, Rodan S, Rodan G, Kimmel D 2009 Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 44:199-207
101. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaissé JM 2003 The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859-867 (Pubitemid 37294969)
102. Sørensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH, Karsdal MA 2007 Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab 25:36-45 (Pubitemid 46012995)
103. Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E 2005 Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36:159-172 (Pubitemid 40128284)
104. Zenger S, Hollberg K, Ljusberg J, Norgård M, Ek-Rylander B, Kiviranta R, Andersson G 2007 Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone 41:820-832 (Pubitemid 47576835)
105. Burr DB 2002 Targeted and nontargeted remodeling. Bone 30:2-4 (Pubitemid 34044293)
106. Parfitt AM 2002 Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 30:5-7 (Pubitemid 34044294)
107. Noble B 2003 Bone microdamage and cell apoptosis. Eur Cell Mater 6:46-55; discussion 55
108. Verborgt O, Gibson GJ, Schaffler MB 2000 Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 15:60-67 (Pubitemid 30026933)
109. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K 2007 Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5:464-475 (Pubitemid 46825494)
110. Talmage RV, Talmage DW 2006 Calcium homeostasis: solving the solubility problem. J Musculoskelet Neuronal Interact 6:402-407 (Pubitemid 46099729)
111. Parfitt AM 2003 Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone 33:259-263 (Pubitemid 37103241)
112. Marenzana M, Shipley AM, Squitiero P, Kunkel JG, Rubinacci A 2005 Bone as an ion exchange organ: evidence for instantaneous cell-dependent calcium efflux from bone not due to resorption. Bone 37:545-554 (Pubitemid 41317327)
113. Dent CE, Smellie JM, Watson L 1965 Studies in osteopetrosis. Arch Dis Child 40:7-15
114. Manolagas SC 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137 (Pubitemid 32275592)
115. Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaissé JM, Foged NT 2003 Transforming growth factor-β controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975-44987 (Pubitemid 37377257)
116. Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, MacKay CA, Van Hul E, Timmermans JP, Vanhoenacker F, Jacobs R, Peruzzi B, Teti A, Helfrich MH, Rogers MJ, Villa A, Van Hul W 2007 Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest 117:919-930 (Pubitemid 46556748)
117. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P 2007 Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem 282:5691-5703 (Pubitemid 47093757)
118. Schlemmer A, Hassager C, Jensen SB, Christiansen C 1992 Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74:476-480
119. Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S 1998 Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102-106 (Pubitemid 28347681)
120. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C 2002 Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57-61 (Pubitemid 34754426)
121. Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C 2002 Mechanism of circadian variation in bone resorption. Bone 30:307-313 (Pubitemid 34044332)
122. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C 2008 Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin Pharmacol 8:5
123. Karsdal MA, Byrjalsen I, Azria M, Arnold M, Choi L, Riis BJ, Christiansen C 2009 Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br J Clin Pharmacol 67:413-420
124. Henriksen DB, Alexandersen P, Byrjalsen I, Hartmann B, Bone HG, Christiansen C, Holst JJ 2004 Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 34:140-147 (Pubitemid 38142442)
125. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C 2007 Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 40:723-729 (Pubitemid 46201945)
126. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C 2009 Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45:833-842
127. Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C 2004 Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531-1538 (Pubitemid 41094356)
128. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230 (Pubitemid 36519939)
129. Clowes JA, Eghbali-Fatourechi GZ, McCready L, Oursler MJ, Khosla S, Riggs BL 2009 Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. Osteoporos Int 20:761-769
130. Taxel P, Kaneko H, Lee SK, Aguila HL, Raisz LG, Lorenzo JA 2008 Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int 19:193-199
131. Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP 2005 Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 20:1659-1668 (Pubitemid 41243554)
132. D'Amelio P, Grimaldi A, Pescarmona GP, Tamone C, Roato I, Isaia G 2005 Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J 19:410-412 (Pubitemid 40316533)
133. Jevon M, Hirayama T, Brown MA, Wass JA, Sabokbar A, Ostelere S, Athenasou NA 2003 Osteoclast formation from circulating precursors in osteoporosis. Scand J Rheumatol 32:95-100 (Pubitemid 36428347)
134. D'Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C, Giribaldi G, Ulliers D, Pescarmona GP, Isaia G 2008 Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 43:92-100
135. Shevde NK, Bendixen AC, Dienger KM, Pike JW 2000 Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 97:7829-7834 (Pubitemid 30460733)
136. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R 2001 Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation. J Biol Chem 276:8836-8840
137. Sørensen MG, Henriksen K, Dziegiel MH, Tankó LB, Karsdal MA 2006 Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol 25:475-483 (Pubitemid 44267068)
138. Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW 2001 Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142:3800-3808 (Pubitemid 32802650)
139. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S 2007 Estrogen prevents bone
140. Bord S, Horner A, Beavan S, Compston J 2001 Estrogen receptors α and β are differentially expressed in developing human bone. J Clin Endocrinol Metab 86:2309-2314 (Pubitemid 32472956)
141. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC 2010 The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 24:323-334
142. Riggs BL, Melton Iii 3rd LJ, Robb RA, Camp JJ, Atkinson EJ, Peterson JM, Rouleau PA, McCollough CH, Bouxsein ML, Khosla S 2004 Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 19:1945-1954 (Pubitemid 41103408)
143. Recker R, Lappe J, Davies KM, Heaney R 2004 Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19:1628-1633 (Pubitemid 41094325)
144. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349 (Pubitemid 26076383)
145. Arlot ME, Delmas PD, Chappard D, Meunier PJ 1990 Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: comparison with normal postmenopausal women. Osteoporos Int 1:41-49
146. Viguet-Carrin S, Garnero P, Delmas PD 2006 The role of collagen in bone strength. Osteoporos Int 17:319-336
147. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W 2005 Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem 51:2348-2353 (Pubitemid 41692580)
148. Saito M, Marumo K 2010 Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195-214
149. Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, Taketomi S 1997 Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8:260-270 (Pubitemid 127455881)
150. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR, Harris TB, Bauer DC 2009 Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 94:2380-2386
151. Raska Jr I, Broulík P 2005 The impact of diabetes mellitus on skeletal health: an established phenomenon with inestablished causes? Prague Med Rep 106:137-148
152. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P 2008 Pentosidine effects on human osteoblasts in vitro. Ann NY Acad Sci 1126:166-172 (Pubitemid 351589306)
153. Henriksen K, Gram J, Neutzsky-Wulff AV, Jensen VK, Dziegiel MH, Bollerslev J, Karsdal MA 2009 Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7. Biochem Biophys Res Commun 378:804-809
154. Taranta A, Migliaccio S, Recchia I, Caniglia M, Luciani M, De Rossi G, Dionisi-Vici C, Pinto RM, Francalanci P, Boldrini R, Lanino E, Dini G, Morreale G, Ralston SH, Villa A, Vezzoni P, Del Principe D, Cassiani F, Palumbo G, Teti A 2003 Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol 162:57-68 (Pubitemid 36050039)
155. Maranda B, Chabot G, Décarie JC, Pata M, Azeddine B, Moreau A, Vacher J 2008 Clinical and cellular manifestations of OSTM1-related infantile osteopetrosis. J Bone Miner Res 23:296-300 (Pubitemid 351160044)
156. Rajapurohitam V, Chalhoub N, Benachenhou N, Neff L, Baron R, Vacher J 2001 The mouse osteopetrotic greylethal mutation induces a defect in osteoclast maturation/function. Bone 28:513-523 (Pubitemid 32410003)
157. Semba I, Ishigami T, Sugihara K, Kitano M 2000 Higher osteoclastic demineralization and highly mineralized cement lines with osteocalcin deposition in a mandibular cortical bone of autosomal dominant osteopetrosis type II: ultrastructural and undecalcified histological investigations. Bone 27:389-395 (Pubitemid 30658122)
158. Garnero P, Thompson E, Woodworth T, Smolen JS 2010 Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 62:33-43
159. Nielsen RH, Karsdal MA, Sørensen MG, Dziegiel MH, Henriksen K 2007 Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival. Biochem Biophys Res Commun 360:834-839 (Pubitemid 47077396)
160. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM 2004 Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883-890 (Pubitemid 38543667)
161. Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, Fortunati D, Ballanti P, Iacobini M, Luciani M, Devito R, Pinto R, Caniglia M, Lanino E, Messina C, Cesaro S, Letizia C, Bianchini G, Fryssira H, Grabowski P, Shaw N, Bishop N, Hughes D, Kapur RP, Datta HK, Taranta A, Fornari R, Migliaccio S, Teti A 2006 Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 43:315-325
162. Soriano P, Montgomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702 (Pubitemid 121001157)
163. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443-448
164. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF, Baron R, Teti A 2000 Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311-320
165. Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK 2002 Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 143:4038-4047 (Pubitemid 35244383)
166. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK 2005 Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584-4596 (Pubitemid 41446596)
167. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO 2005 Essential role of β-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168 (Pubitemid 40805677)
168. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler- Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523 (Pubitemid 33152786)
169. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W 2003 Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771 (Pubitemid 36255977)
170. Bollerslev J, Ueland T, Odgren PR 2003 Serum levels of TGF-β and fibronectin in autosomal dominant osteopetrosis in relation to underlying mutations and well-described murine counterparts. Crit Rev Eukaryot Gene Expr 13:163-171 (Pubitemid 38009166)
171. Sarnsethsiri P, Hitt OK, Eyring EJ, Frost HM 1971 Tetracycline-based study of bone dynamics in pycnodysostosis. Clin Orthop Relat Res 74:301-312
172. Ho N, Punturieri A, Wilkin D, Szabo J, Johnson M, Whaley J, Davis J, Clark A, Weiss S, Francomano C 1999 Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein. J Bone Miner Res 14:1649-1653 (Pubitemid 29455812)
173. Hou WS, Brömme D, Zhao Y, Mehler E, Dushey C, Weinstein H, Miranda CS, Fraga C, Greig F, Carey J, Rimoin DL, Desnick RJ, Gelb BD 1999 Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest 103:731-738
174. Chavassieux P, Asser Karsdal M, Segovia-Silvestre T, Neutzsky-Wulff AV, Chapurlat R, Boivin G, Delmas PD 2008 Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 23:1076-1083 (Pubitemid 351915730)
175. Everts V, Aronson DC, Beertsen W 1985 Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int 37:25-31 (Pubitemid 15102232)
176. Li CY, Jepsen KJ, Majeska RJ, Zhang J, Ni R, Gelb BD, Schaffler MB 2006 Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 21:865-875 (Pubitemid 43787993)
177. Fratzl-Zelman N, Valenta A, Roschger P, Nader A, Gelb BD, Fratzl P, Klaushofer K 2004 Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 89:1538-1547 (Pubitemid 38507900)
178. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA 2010 Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937-947
179. Pennypacker B, Wesolowski G, Heo J, Duong LT 2009 Effects of odanacatib on central femur cortical bone in estrogen-deficient adult rhesus monkeys. J Bone Miner Res 24(Suppl 1):1171 (Abstract)
180. Cusick T, Pennypacker B, Scott K, Duong LT, Kimmel D 2009 Effects of odanacatib on bone mass, turnover and strength in the femoral neck of estrogen deficient adult rhesus monkeys. J Bone Miner Res 24(Suppl 1):FR0416 (Abstract)
181. Scott K, Cusick T, Duong LT, Pennypacker B, Kimmel D 2009 Effects of odanacatib on bone turnover and osteoclast morphology in the lumbar vertebra of ovariectomized adult rhesus monkeys. J Bone Miner Res 24(Suppl 1):SU0227 (Abstract)
182. Helfrich M, Crockett JC, Hocking LJ, Coxon FP 2007 The pathogenesis of osteoclast diseases: some knowns, but still many unknowns. BoneKEy-Osteovision 4:61-77
183. Roodman GD 1996 Paget's disease and osteoclast biology. Bone 19:209-212 (Pubitemid 26302603)
184. Goode A, Layfield R 2010 Recent advances in understanding the molecular basis of Paget's disease of bone. J Clin Pathol 63:199-203
185. Roodman GD, Windle JJ 2005 Paget disease of bone. J Clin Invest 115:200-208 (Pubitemid 40385458)
186. Ralston SH, Langston AL, Reid IR 2008 Pathogenesis and management of Paget's disease of bone. Lancet 372:155-163 (Pubitemid 351952259)
187. Neale SD, Smith R, Wass JA, Athanasou NA 2000 Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. Bone 27:409-416 (Pubitemid 30658125)
188. Singer FR, Mills BG, Gruber HE, Windle JJ, Roodman GD 2006 Ultrastructure of bone cells in Paget's disease of bone. J Bone Miner Res 21(Suppl 2):P51-P54
189. Kurihara N, Hiruma Y, Zhou H, Subler MA, Dempster DW, Singer FR, Reddy SV, Gruber HE, Windle JJ, Roodman GD 2007 Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 117:133-142 (Pubitemid 46048460)
190. Hiruma Y, Kurihara N, Subler MA, Zhou H, Boykin CS, Zhang H, Ishizuka S, Dempster DW, Roodman GD, Windle JJ 2008 A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 17:3708-3719
191. Gennari L, Merlotti D, Mossetti G, Rendina D, De Paola V, Martini G, Nuti R 2009 The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. Mini Rev Med Chem 9:1052-1063
192. Clines GA, Guise TA 2008 Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10:e7
193. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM 2006 Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12:6213s-6216s
194. Hu MI, Lu H, Gagel RF 2010 Cancer therapies and bone health. Curr Rheumatol Rep 12:177-185
195. Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P 2008 Biology of breast cancer bone metastasis. Cancer Biol Ther 7:3-9
196. Lipton A 2006 Future treatment of bone metastases. Clin Cancer Res 12:6305s-6308s
197. Clezardin P, Teti A 2007 Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 24:599-608 (Pubitemid 50003596)
198. Cicek M, Oursler MJ 2006 Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev 25:635-644 (Pubitemid 46071868)
199. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tankó LB 2006 The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32-38
200. Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, Qvist P, Tankó LB, Byrjalsen I 2006 α CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prev 15:1392-1395
201. Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E 2007 Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178:849-853 (Pubitemid 47211070)
202. Winding B, NicAmhlaoibh R, Misander H, Høegh-Andersen P, Andersen TL, Holst-Hansen C, Heegaard AM, Foged NT, Brünner N, Delaissé JM 2002 Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 8:1932-1939 (Pubitemid 34633756)
203. Le Gall C, Bonnelye E, Clézardin P 2008 Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2:218-222
204. Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P 2007 A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 67:9894-9902 (Pubitemid 47621238)
205. Coussens LM, Fingleton B, Matrisian LM 2002 Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392 (Pubitemid 34270240)
206. Pavlaki M, Zucker S 2003 Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22:177-203 (Pubitemid 36561057)
207. Coleman R, Gnant M 2009 New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care 3:213-218
208. Machado M, Cruz LS, Tannus G, Fonseca M 2009 Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther 31:962-979
209. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S 2009 Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564-1571
210. Kearns AE, Khosla S, Kostenuik PJ 2008 Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155-192 (Pubitemid 351519689)
211. Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V, Ebert R, Jakob F, Hofbauer LC 2010 Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287:109-116
212. Schett G, Teitelbaum SL 2009 Osteoclasts and arthritis. J Bone Miner Res 24:1142-1146
213. Schett G 2007 Erosive arthritis. Arthritis Res Ther 9(Suppl 1):S2
214. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR 1998 Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152:943-951 (Pubitemid 28173356)
215. Feldmann M, Brennan FM, Maini RN 1996 Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440 (Pubitemid 26130190)
216. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G 1991 Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031 (Pubitemid 21905432)
217. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P 2009 A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 181:787-796
218. Licastro F, Chiappelli M, Ianni M, Porcellini E 2009 Tumor necrosis factor-α antagonists: differential clinical effects by different biotechnological molecules. Int J Immunopathol Pharmacol 22:567-572
219. Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, Benoist C, Gravallese EM 2001 TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159:1689-1699 (Pubitemid 33062512)
220. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT 2002 Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161:1419-1427
221. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G 2002 Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 110:1419-1427 (Pubitemid 35396913)
222. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R 2008 Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299-1309 (Pubitemid 351705919)
223. Zwerina J, Redlich K, Polzer K, Joosten L, Krönke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G 2007 TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 104:11742-11747
224. Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O'Connor PJ, Grainger AJ, Emery P 2006 Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54:1410-1414
225. Breuil V, Euller-Ziegler L 2006 Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 73:349-354
226. Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA 2006 Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 17:716-723
227. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253-1263
228. Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E 2004 Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 50:2338-2346 (Pubitemid 38924414)
229. Herrak P, Görtz B, Hayer S, Redlich K, Reiter E, Gasser J, Bergmeister H, Kollias G, Smolen JS, Schett G 2004 Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 50:2327-2337 (Pubitemid 38924413)
230. Morko JP, Söderström M, Säämänen AM, Salminen HJ, Vuorio EI 2004 Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 63:649-655 (Pubitemid 38658393)
231. Morko J, Kiviranta R, Joronen K, Säämänen AM, Vuorio E, Salminen-Mankonen H 2005 Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum 52:3713-3717 (Pubitemid 41798207)
232. Schurigt U, Hummel KM, Petrow PK, Gajda M, Stöckigt R, Middel P, Zwerina J, Janik T, Bernhardt R, Schüler S, Scharnweber D, Beckmann F, Saftig P, Kollias G, Schett G, Wiederanders B, Bräuer R 2008 Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. Arthritis Rheum 58:422-434 (Pubitemid 351294877)
233. Hou WS, Li Z, Gordon RE, Chan K, Klein MJ, Levy R, Keysser M, Keyszer G, Brömme D 2001 Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol 159:2167-2177 (Pubitemid 33104271)
234. Yasuda Y, Kaleta J, Brömme D 2005 The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973-993 (Pubitemid 40703885)
235. Ainola M, Valleala H, Nykänen P, Risteli J, Hanemaaijer R, Konttinen YT 2008 Erosive arthritis in a patient with pycnodysostosis: an experiment of nature. Arthritis Rheum 58:3394-3401
236. Svelander L, Erlandsson-Harris H, Astner L, Grabowska U, Klareskog L, Lindstrom E, Hewitt E 2009 Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. Eur J Pharmacol 613:155-162
237. Salminen-Mankonen HJ, Morko J, Vuorio E 2007 Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 8:315-323
238. Hakala M, Risteli J, Aman S, Kautiainen H, Korpela M, Hannonen P, Leirisalo-Repo M, Laasonen L, Paimela L, Möttönen T 2008 Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression. Scand J Rheumatol 37:90-93 (Pubitemid 351536071)
239. Sassi ML, Aman S, Hakala M, Luukkainen R, Risteli J 2003 Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis. Clin Chem Lab Med 41:1038-1044 (Pubitemid 37062995)
240. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T 2008 Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353-357 (Pubitemid 351281270)
241. Kadono Y, Tanaka S, Nishino J, Nishimura K, Nakamura I, Miyazaki T, Takayanagi H, Nakamura K 2009 Rheumatoid arthritis associated with osteopetrosis. Mod Rheumatol 19:687-690
242. Russell RG, Watts NB, Ebetino FH, Rogers MJ 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759
243. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480 (Pubitemid 27425772)
244. Recker RR, Weinstein RS, Chesnut 3rd CH, Schimmer RC, Mahoney P, Hughes C, Bonvoisin B, Meunier PJ 2004 Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15:231-237 (Pubitemid 38391539)
245. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16
246. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, Vuori I, Vaananen HK, Halleen JM 2005 Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804-1812 (Pubitemid 41361881)
247. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A 2004 Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34:187-194 (Pubitemid 38142448)
248. Muñoz-Torres M, Reyes-García R, Mezquita-Raya P, Fernández-García D, Alonso G, Luna Jde D, Ruiz-Requena ME, Escobar-Jiménez F 2009 Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas 64:188-192
249. D'Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G 2008 Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 23:373-379 (Pubitemid 351304667)
250. D'Amelio P, Grimaldi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC 1 December 2009 Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int 10.1007/s00198-009-1129-1
251. Weinstein RS, Roberson PK, Manolagas SC 2009 Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53-62
252. Mori S, Harruff R, Ambrosius W, Burr DB 1997 Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 21:521-526 (Pubitemid 28029695)
253. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD 2007 Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22:1502-1509 (Pubitemid 351229320)
254. Burr DB, Allen MR 2008 Low bone turnover and microdamage? How and where to assess it? J Bone Miner Res 23:1150-1151; author reply 1152-1153
255. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C 1999 Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363-2368
256. Ravn P, Clemmesen B, Christiansen C 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237-244 (Pubitemid 29094566)
257. Ravn P, Thompson DE, Ross PD, Christiansen C 2003 Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33:150-158 (Pubitemid 36957958)
258. Eriksen EF, Melsen F, Sod E, Barton I, Chines A 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620-625 (Pubitemid 35449706)
259. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938 (Pubitemid 46021497)
260. Durie BG, Katz M, Crowley J 2005 Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102
261. Watts NB, Diab DL 2010 Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555-1565
262. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491 (Pubitemid 351229318)
263. Cheng A, Daly CG, Logan RM, Stein B, Goss AN 2009 Alveolar bone and the bisphosphonates. Aust Dent J 54(Suppl 1):S51-S61
264. Tran Van PT, Vignery A, Baron R 1982 Cellular kinetics of the bone remodeling sequence in the rat. Anat Rec 202:445-451 (Pubitemid 12144354)
265. Tran Van P, Vignery A, Baron R 1982 An electron-microscopic study of the bone-remodeling sequence in the rat. Cell Tissue Res 225:283-292 (Pubitemid 12060724)
266. Baron R, Neff L, Tran Van P, Nefussi JR, Vignery A 1986 Kinetic and cytochemical identification of osteoclast precursors and their differentiation into multinucleated osteoclasts. Am J Pathol 122:363-378 (Pubitemid 16121700)
267. Favia G, Pilolli GP, Maiorano E 2009 Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45:406-413
268. Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, Tregnaghi A, Pietrogrande F, Procopio O, Saia G, Ferretti M, Bedogni G, Chiarini L, Ferronato G, Ninfo V, Lo Russo L, Lo Muzio L, Nocini PF 2008 Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105:358-364
269. Hansen T, Kunkel M, Weber A, James Kirkpatrick C 2006 Osteonecrosis of the jaws in patients treated with bisphosphonates- histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155-160
270. Ramalho AC, Couttet P, Baudoin C, Morieux C, Graulet AM, de Vernejoul MC, Cohen-Solal ME 2002 Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur Cytokine Netw 13:39-45 (Pubitemid 34535570)
271. Saintier D, Burde MA, Rey JM, Maudelonde T, de Vernejoul MC, Cohen-Solal ME 2004 17β-Estradiol downregulates β3-integrin expression in differentiating and mature human osteoclasts. J Cell Physiol 198:269-276 (Pubitemid 38133960)
272. Michael H, Härkönen PL, Väänänen HK, Hentunen TA 2005 Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 20:2224-2232 (Pubitemid 41698785)
273. Michael H, Härkönen PL, Kangas L, Väänänen HK, Hentunen TA 2007 Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 151:384-395 (Pubitemid 46842673)
274. Taranta A, Brama M, Teti A, De luca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S 2002 The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30:368-376 (Pubitemid 34150159)
275. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC 1991 Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 88:6613-6617 (Pubitemid 21914998)
276. Oursler MJ, Pederson L, Fitzpatrick L, Riggs BL, Spelsberg T 1994 Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA 91:5227-5231 (Pubitemid 24174299)
277. Oursler MJ, Pederson L, Pyfferoen J, Osdoby P, Fitzpatrick L, Spelsberg TC 1993 Estrogen modulation of avian osteoclast lysosomal gene expression. Endocrinology 132:1373-1380 (Pubitemid 23068662)
278. Kremer M, Judd J, Rifkin B, Auszmann J, Oursler MJ 1995 Estrogen modulation of osteoclast lysosomal enzyme secretion. J Cell Biochem 57:271-279
279. Parikka V, Lehenkari P, Sassi ML, Halleen J, Risteli J, Härkönen P, Väänänen HK 2001 Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology 142:5371-5378 (Pubitemid 33131970)
280. Ott SM, Oleksik A, Lu Y, Harper K, Lips P 2002 Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17:341-348 (Pubitemid 34087667)
281. Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F 1989 A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 10:313-320 (Pubitemid 20072023)
282. Patel S, Pazianas M, Tobias J, Chambers TJ, Fox S, Chow J 1999 Early effects of hormone replacement therapy on bone. Bone 24:245-248 (Pubitemid 29094567)
283. Eriksen EF, Langdahl B, Vesterby A, Rungby J, Kassem M 1999 Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women. J Bone Miner Res 14:1217-1221 (Pubitemid 29314067)
284. Vedi S, Purdie DW, Ballard P, Bord S, Cooper AC, Compston JE 1999 Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy. Osteoporos Int 10:52-58 (Pubitemid 29428015)
285. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645 (Pubitemid 29384151)
286. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW 1999 Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 10:330-336 (Pubitemid 29476199)
287. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL 1998 Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747-1754 (Pubitemid 28492005)
288. Chambers TJ, Moore A 1983 The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 57:819-824
289. Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y, Hori M, Suda T 1996 Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology 137:4685-4690 (Pubitemid 26403306)
290. Shyu JF, Shih C, Tseng CY, Lin CH, Sun DT, Liu HT, Tsung HC, Chen TH, Lu RB 2007 Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities. Bone 40:1329-1342 (Pubitemid 46550990)
291. Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, Byrjalsen I, Azria M, Riis BJ, Qvist P, Christiansen C 2010 Lessons learned from the development of oral calcitonin: the first tablet formulation of a peptide in phase III clinical trials. J Clin Pharmacol 10.1177/0091270010372625
292. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C 2008 Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol 8:12
293. Kung AW, Pasion EG, Sofiyan M, Lau EM, Tay BK, Lam KS, Wilawan K, Ongphiphadhanakul B, Thiebaud D 2006 A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 22:929-937 (Pubitemid 43875560)
294. Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS 2006 Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 17:373-378
295. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E 2002 A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 17:521-527 (Pubitemid 34171767)
296. Chesnut 3rd CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L 2005 Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res 20:1548-1561 (Pubitemid 41243544)
297. Ikegame M, Ejiri S, Ozawa H 2004 Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors. Bone 35:27-33 (Pubitemid 38789145)
298. Jiang Y, Zhao J, Geusens P, Liao EY, Adriaensens P, Gelan J, Azria M, Boonen S, Caulin F, Lynch JA, Ouyang X, Genant HK 2005 Femoral neck trabecular microstructure in ovariectomized ewes treated with calcitonin: MRI microscopic evaluation. J Bone Miner Res 20:125-130 (Pubitemid 41716227)
299. Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF 2002 Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 110:1849-1857 (Pubitemid 36076492)
300. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre-Medhin S, Galson DL, Zajac JD, Karsenty G 2004 Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 164:509-514 (Pubitemid 38233312)
301. Davey RA, Turner AG, McManus JF, Chiu WS, Tjahyono F, Moore AJ, Atkins GJ, Anderson PH, Ma C, Glatt V, MacLean HE, Vincent C, Bouxsein M, Morris HA, Findlay DM, Zajac JD 2008 Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res 23:1182-1193 (Pubitemid 352040174)
302. Turner C, Tjahyono A, Moore A, Findlay D, Morris H, Zajac J, Davey R 2009 The calcitonin receptor expressed by osteoclasts plays a biological role to protect against induced hypercalcemia in mice. J Bone Miner Res 24(Suppl 1):1049 (Abstract)
303. Karsdal MA, Byrjalsen I, Leeming DJ, Delmas PD, Christiansen C 2008 The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int 19:1355-1361
304. Holtrop ME, King GJ, Cox KA, Reit B 1979 Time-related changes in the ultrastructure of osteoclasts after injection of parathyroid hormone in young rats. Calcif Tissue Int 27:129-135 (Pubitemid 10220028)
305. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE 2001 Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054
306. Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH 2000 Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27:311-318 (Pubitemid 30458828)
307. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253 (Pubitemid 40863814)
308. Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J 2009 Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24:1358-1368
309. Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638
310. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446 (Pubitemid 29534328)
311. Luiz de Freitas PH, Li M, Ninomiya T, Nakamura M, Ubaidus S, Oda K, Udagawa N, Maeda T, Takagi R, Amizuka N 2009 Intermittent PTH administration stimulates pre-osteoblastic proliferation without leading to enhanced bone formation in osteoclast-less c-fos(-/-) mice. J Bone Miner Res 24:1586-1597
312. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215 (Pubitemid 37152030)
313. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226 (Pubitemid 37152031)
314. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751 (Pubitemid 41094385)
315. Johnston S, Andrews S, Shen V, Cosman F, Lindsay R, Dempster DW, Iida-Klein A 2007 The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. Endocrinology 148:4466-4474 (Pubitemid 47295697)
316. Samadfam R, Xia Q, Goltzman D 2007 Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55-63 (Pubitemid 46032597)
317. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468 (Pubitemid 38133766)
318. Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K, Reginster JY, Boonen S 2006 Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21:1113-1120
319. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822 (Pubitemid 40686329)
320. Seeman E, Boonen S, Borgström F, Vellas B, Aquino JP, Semler J, Benhamou CL, Kaufman JM, Reginster JY 2010 Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 46:1038-1042
321. Ferrari S 2009 Continuous broad protection against osteoporotic fractures with strontium ranelate. Rheumatology (Oxford) 48(Suppl 4):iv20 -iv24
322. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP, Delmas PD, Meunier PJ 2008 Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215-222 (Pubitemid 351160035)
323. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY 2002 Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060-2066 (Pubitemid 34521489)
324. Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G 2009 Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 60:2747-2756
325. Bruyére O, Collette J, Rizzoli R, Decock C, Ortolani S, Cormier C, Detilleux J, Reginster JY 2010 Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int 21:1031-1036
326. Bonnelye E, Chabadel A, Saltel F, Jurdic P 2008 Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129-138 (Pubitemid 350297175)
327. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517-523 (Pubitemid 26257871)
328. Takahashi N, Sasaki T, Tsouderos Y, Suda T 2003 S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18:1082-1087 (Pubitemid 37294946)
329. Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F, Wattel A, Kamel S, Terwilliger EF, Brown EM, Brazier M 2009 The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 284:575-584
330. Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS 2009 Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157:1291-1300
331. Engvall IL, Svensson B, Tengstrand B, Brismar K, Hafström I 2008 Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 10:R128
332. Caplan L, Saag KG 2009 Glucocorticoids and the risk of osteoporosis. Expert Opin Drug Saf 8:33-47
333. Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328 (Pubitemid 47389469)
334. van Brussel MS, Bultink IE, Lems WF 2009 Prevention of glucocorticoid-induced osteoporosis. Expert Opin Pharmacother 10:997-1005
335. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282 (Pubitemid 28335186)
336. Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schüler C, Stolina M, Kostenuik PJ, Erben RG 2009 Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 60:1427-1437
337. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS 2006 Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147:5592-5599 (Pubitemid 44833476)
338. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE 2008 Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 58:1674-1686 (Pubitemid 351847520)
339. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC 2002 Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041-1048 (Pubitemid 34408579)
340. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL 2006 Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152-2160 (Pubitemid 44162324)
341. Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS 2005 Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20:390-398 (Pubitemid 40293487)
342. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389 (Pubitemid 30666099)
343. Soares-Schanoski A, Gómez-Piña V, del Fresno C, Rodríguez-Rojas A, García F, Glaría A, Sánchez M, Vallejo-Cremades MT, Baos R, Fuentes-Prior P, Arnalich F, López-Collazo E 2007 6-Methylprednisolone down-regulates IRAK-M in human and murine osteoclasts and boosts bone-resorbing activity: a putative mechanism for corticoid-induced osteoporosis. J Leukoc Biol 82:700-709 (Pubitemid 47367162)
344. Søe K, Delaissé JM 30 April 2010 Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J Bone Miner Res 10.1002/jbmr.113
345. Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A 2004 Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89:4923-4928 (Pubitemid 39391429)
346. Minisola S, Del Fiacco R, Piemonte S, Iorio M, Mascia ML, Fidanza F, Cipriani C, Raso I, Porfiri ML, Francucci CM, D'Erasmo E, Romagnoli E 2008 Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest 31:28-32
347. Dalle Carbonare L, Bertoldo F, Valenti MT, Zenari S, Zanatta M, Sella S, Giannini S, Cascio VL 2005 Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 36:645-652 (Pubitemid 41745029)
348. Stellon AJ, Webb A, Compston JE 1988 Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut 29:378-384 (Pubitemid 18082156)
349. Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ 2009 Onceweekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705-1714
350. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, Halloran BP 2002 Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17:1570-1578
351. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
352. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK 2009 Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182-195
353. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149-2157 (Pubitemid 351831529)
354. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831 (Pubitemid 43290920)
355. Ominsky MS, Schroeder J, Jolette J, Smith SY, Farrell DJ, Atkinson JE, Kostenuik PJ 2007 Decreased bone turnover and porosity are associated with improved bone strength in ovariectomized (OVX) cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. J Bone Miner Res 22:S126 (Abstract)
356. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J 2000 Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367-373 (Pubitemid 30136127)
357. Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ 2008 Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 42:200-211 (Pubitemid 350302017)
358. Chappard D, Libouban H, Mindeholm L, Baslé MF, Legrand E, Audran M 2010 The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients. Microsc Res Tech 73:726-732
359. Adams CS, Shapiro IM 2003 Mechanisms by which extracellular matrix components induce osteoblast apoptosis. Connect Tissue Res 44(Suppl 1):230-239 (Pubitemid 36395451)
360. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JM, Gillespie MT, Martin TJ, Sims NA 2008 Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 23:2025-2032
361. Gottschalck IB, Jeppesen PB, Hartmann B, Holst JJ, Henriksen DB 2008 Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand J Gastroenterol 43:1304-1310
362. Gottschalck IB, Jeppesen PB, Holst JJ, Henriksen DB 2008 Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scand J Gastroenterol 43:929-937
363. Sørensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA 2007 Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res 22:1640-1648 (Pubitemid 351229334)
364. Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Hélix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiødt CB, Sørensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaissé JM, Engsig MT, Karsdal MA 2004 The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144-1153 (Pubitemid 41110567)
365. Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M, Farina C 2000 A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 106:309-318 (Pubitemid 30483135)
366. Rzeszutek K, Sarraf F, Davies JE 2003 Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth. J Craniofac Surg 14:301-307
367. Schaller S, Henriksen K, Sørensen MG, Karsdal MA 2005 The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment. Drug News Perspect 18:489-495 (Pubitemid 43094116)
368. Brown EM 2007 The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Sub-cell Biochem 45:139-167
369. Martin TJ 2005 Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 115:2322-2324 (Pubitemid 41266192)
370. Kramer I, Keller H, Leupin O, Kneissel M 2010 Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 21:237-244
371. Thompson ER, Baylink DJ, Wergedal JE 1975 Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in the rat. Endocrinology 97:283-289
372. Howard GA, Bottemiller BL, Turner RT, Rader JI, Baylink DJ 1981 Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism. Proc Natl Acad Sci USA 78:3204-3208 (Pubitemid 11032017)
373. Lazowski DA, Fraher LJ, Hodsman A, Steer B, Modrowski D, Han VK 1994 Regional variation of insulin-like growth factor-I gene expression in mature rat bone and cartilage. Bone 15:563-576 (Pubitemid 24249216)
374. Robinson JA, Riggs BL, Spelsberg TC, Oursler MJ 1996 Osteoclasts and transforming growth factor-β: estrogen-mediated isoform-specific regulation of production. Endocrinology 137:615-621
375. Karsdal MA, Fjording MS, Foged NT, Delaissé JM, Lochter A 2001 Transforming growth factor-β-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J Biol Chem 276:39350-39358
376. Mundy GR, Bonewald LF 1990 Role of TGF β in bone remodeling. Ann NY Acad Sci 593:91-97
377. Baylink DJ, Finkelman RD, Mohan S 1993 Growth factors to stimulate bone formation. J Bone Miner Res 8(Suppl 2):S565-S572 (Pubitemid 24015250)
378. Hayden JM, Mohan S, Baylink DJ 1995 The insulin-like growth factor system and the coupling of formation to resorption. Bone 17:93S-98S
379. Janssens K, ten Dijke P, Janssens S, Van Hul W 2005 Transforming growth factor-β1 to the bone. Endocr Rev 26:743-774
380. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL 2002 Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005-44012 (Pubitemid 36157826)